Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co. Inc.

www.merck.com

Latest From Genentech Inc.

Celgene Eases Angst Over Otezla, Sets The Stage For Growth

Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.

Sales & Earnings Business Strategies

Policy Prescriptions: User Fees, Biosimilars, Brexit

US FDA extends its own user fee deadline; biosimilars earn a dubious milestone; and EMA unveils some contingency planning for Brexit. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet

FDA Advisory Committees

Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns

News and highlights about novel agents from our FDA Performance Tracker.

Approvals Complete Response Letters

2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead

Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.

Sales & Earnings Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register